# Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

> **NCT02419742** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 110 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Docetaxel
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT02419742
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-18
- **Primary completion:** 2021-06-24
- **Final completion:** 2021-06-24
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2022-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02419742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02419742, "Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02419742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*